Hadas Weinstein-Marom

Tal Medical, Inc. operates as a clinical stage medical device company. It develops novel, non contact, neuromodulatory devices for the treatment of psychiatric and neurological disorders. The firm focuses on the development of LFMS for the treatment of major depressive disorder and bipolar depression. The company was founded by Daphne Zohar, Steven Marc Paul, Andrew Miller, Eric Elenko and Nessan Bermingham in 2010 and is headquartered in Boston, MA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA.

PricewaterhouseCoopers LLP engages in the provision of accounting services. Its services include audit and assurance, accounting advisory, risk assurance, tax management, corporate insolvency, life cycle assessment, forensic services, private equity advisory, and financial reporting valuations. The company is headquartered in London, the United Kingdom.

Benaroya Research Institute at Virginia Mason is a non-profit organization that operates as a medical research institute. It conducts reserach for eliminating autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis, and immune system diseases such as allergies and asthma. The company was founded in 1956 and is headquartered in Seattle, WA.

Virginia Mason Foundation provides philanthropic support for extraordinary patient care at Virginia Mason. The company is headquartered in Seattle, WA.

ImmPACT-Bio Ltd. develops therapies to treat cancer. Its chimeric antigen receptor T-cell (CAR-T) therapy addresses the need to differentiate cancerous from non-cancerous tissues. The company was founded by Gideon Gross in April 2017 and is headquartered in Nes Ziona, Israel.

Alia Therapeutics Srl engages in experimental research activities in the field of biotechnology. It specializes in the identification of new technologies for genome modification. The company was founded by Gianluca Petris, Antonio Casini, and Anna Cereseto and is headquartered in Trento, Italy.

RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA.

Nivien Therapeutics Co. is an American biotechnology company that operates in the field of biotechnology. The private company was founded by Nathaniel Brooks Horwitz.

Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau.

DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022.

Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz.